European Archives - Page 993 of 1208 - European Medical Journal

EMJ Rheumatology 4.1 2017

A warm welcome to EMJ Rheumatology 4.1, a journal that aims to bring healthcare professionals up to date on the latest advances in this fast-paced field.

Review of the 18th European League Against Rheumatology Congress 2017

The 2017 event marked the 70th anniversary of the EULAR society, and the organising committee ensured that the celebrations did not go unnoticed!

Prevalence and Significance of Anti-Saccharomyces Cerevisiae Antibodies in Primary Sjögren’s Syndrome

Saccharomyces cerevisiae is a common yeast used in the food industry.

Development of a 37-Channel Mass Cytometry (CyTOF) Panel to Predict Treatment Response in Rheumatoid Arthritis

Treating the inflammation of rheumatoid arthritis early leads to less disability and improved patient outcomes.

Biosimilars and Switching: What is your Perspective?

The licensing of biosimilars heralds the start of a new era for physicians treating immune and inflammatory diseases.

Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting The ‘Nocebo’ Effect

Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality.

Rheumatosphere: Reach New Heights in Diagnosis and Treatment of Arthritis by Engaging, Empowering, and Inspiring

Rheumatosphere is an initiative started in Glasgow, UK, in 2012; its aim is to raise awareness about arthritis and arthritis-related research.

The Patient’s Perspective on Psoriatic Arthritis: What more can Rheumatologists do to Optimise Disease Management?

The symposium at the EULAR 2017 congress aimed to provide insights into the burden of psoriatic arthritis on patients’ daily lives, including the…

Longitudinal Analysis of the Gastrointestinal Microbiota in Systemic Sclerosis

Understanding the interplay between the immune system and gastrointestinal tract microbiota is an evolving area of research.

Drug Trough Levels and Antidrug Antibodies in Nonselected Ankylosing Spondylitis Patients Using Subcutaneous Anti-TNF Drugs

Immunisation of biological drugs can result in reduced efficacy of treatment and an increased risk of adverse effects.